Related Experiment Video
Updated: Jan 19, 2026

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies
Published on: January 28, 2014
Biomarkers as Surrogate Endpoints: Ongoing Opportunities for Validation.
Audrey D Zhang1, Joseph S Ross1
1Audrey D. Zhang, A.B., is affiliated with New York University School of Medicine, New York, NY and Center for Outcomes Research and Evaluation, Yale-New Haven Hospital), all New Haven, Connecticut. Joseph S. Ross, M.D., M.H.S., is affiliated with Section of General Internal Medicine, and the National Clinician Scholars Program, Department of Internal Medicine, Yale School of Medicine; Department of Health Policy and Management, Yale School of Public Health; Center for Outcomes Research and Evaluation, Yale-New Haven Hospital, all New Haven, Connecticut.
Biomarker surrogate endpoints help estimate clinical trial benefits but face reliability questions. Ongoing validation efforts are crucial, especially as regulatory bodies increasingly support their use.
Area of Science:
- Biostatistics
- Clinical Trials
- Biomarker Research
Background:
- Surrogate endpoints are frequently used in clinical trials to predict clinical benefit.
- The reliability of surrogate endpoints remains a significant concern in medical research.
Purpose of the Study:
- To discuss the ongoing opportunities for validating surrogate endpoints.
- To examine the role of surrogate endpoints within the current regulatory landscape.
Main Methods:
- Literature review on surrogate endpoint validation.
- Analysis of the current regulatory environment and its impact on biomarker use.
Main Results:
- Surrogate endpoints offer a pathway to estimate clinical benefit in trials.
- Despite reliability questions, regulatory bodies are increasingly championing their use.
Conclusions:
- Continued validation of surrogate endpoints is essential.
- The regulatory environment presents both challenges and opportunities for biomarker-driven clinical trials.
More Related Videos
Related Concept Videos
Bioavailability Study Design: Healthy Subjects Versus Patients
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Drug Products: Biologics, Biosimilars and Interchangeables
Measurement of Bioavailability: Pharmacodynamic Methods
Blood Studies for Cardiovascular System I: Cardiac Biomarkers
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
Bioequivalence of Drugs: Drugs with Multiple Indications

